Targeting the Transforming Growth Factor-β pathway inhibits human basal-like breast cancer metastasis

Molecular Cancer

Volumn 9, Issue , 2010, Pages

  Ganapathy, Vidya ^a   Ge, Rongrong ^a   Grazioli, Alison ^a   Xie, Wen ^a   Banach Petrosky, Whitney ^a   Kang, Yibin ^b   Lonning, Scott ^c   McPherson, John ^c   Yingling, Jonathan M ^d   Biswas, Swati ^e   Mundy, Gregory R ^e   Reiss, Michael ^a  

^a ROBERT WOOD JOHNSON MEDICAL SCHOOL   (United States)

^b PRINCETON UNIVERSITY   (United States)

^c GENZYME CORPORATION   (United States)

^d ELI LILLY AND COMPANY   (United States)

^e VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIMETASTATIC AGENT; LY 2109761; MONOCLONAL ANTIBODY 1D11; SMAD PROTEIN; TRANSFORMING GROWTH FACTOR BETA; TRANSFORMING GROWTH FACTOR BETA ANTIBODY; TRANSFORMING GROWTH FACTOR BETA INHIBITOR; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; LY2109761; MONOCLONAL ANTIBODY; PYRAZOLE DERIVATIVE; PYRROLE DERIVATIVE;

ARTICLE; BONE METASTASIS; BREAST CARCINOMA; CANCER CELL; CANCER INHIBITION; CANCER INVASION; CARCINOMA CELL; CELL ACTIVITY; CELL CLONE; CELL COUNT; CELL MIGRATION; CONTROLLED STUDY; DRUG MECHANISM; DRUG TARGETING; HUMAN; HUMAN CELL; LUNG METASTASIS; MDA MB 231 CELL; METASTASIS POTENTIAL; OSTEOCLAST; OSTEOLYSIS; PROTEIN AGGREGATION; PROTEIN PHOSPHORYLATION; PROTEIN TARGETING; TUMOR VASCULARIZATION; ANIMAL; BREAST TUMOR; CELL MOTION; CELL PROLIFERATION; DRUG ANTAGONISM; DRUG EFFECT; DRUG SCREENING; FEMALE; METABOLISM; METASTASIS; MOUSE; NEOVASCULARIZATION (PATHOLOGY); NUDE MOUSE; PATHOLOGY; PHYSIOLOGY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; TUMOR CELL LINE; WESTERN BLOTTING;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; BLOTTING, WESTERN; BREAST NEOPLASMS; CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; FEMALE; HUMANS; MICE; MICE, NUDE; NEOPLASM METASTASIS; NEOVASCULARIZATION, PATHOLOGIC; PYRAZOLES; PYRROLES; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; TRANSFORMING GROWTH FACTOR BETA; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 77952609184     PISSN: None     EISSN: 14764598     Source Type: Journal    
DOI: 10.1186/1476-4598-9-122     Document Type: Article

References (62)

1. Strange R, Li F, Saurer S, Burkhardt A, Friis RR. Apoptotic cell death and tissue remodelling during mouse mammary gland involution. Development 1992, 115:49-58.
2. Gorska AE, Joseph H, Derynck R, Moses HL, Serra R. Dominant-negative interference of the transforming growth factor beta type II receptor in mammary gland epithelium results in alveolar hyperplasia and differentiation in virgin mice. Cell Growth Differ 1998, 9:229-238.
3. Barcellos-Hoff MH, Akhurst RJ. Transforming growth factor-beta in breast cancer: too much, too late. Breast Cancer Res 2009, 11:202. 10.1186/bcr2224, 2687712, 19291273.
4. Roberts AB, Tian F, Byfield SD, Stuelten C, Ooshima A, Saika S, Flanders KC. Smad3 is key to TGF-beta-mediated epithelial-to-mesenchymal transition, fibrosis, tumor suppression and metastasis. Cytokine Growth Factor Rev 2006, 17:19-27. 10.1016/j.cytogfr.2005.09.008, 16290023.
5. Piek E, Moustakas A, Kurisaki A, Heldin CH, ten Dijke P. TGF-(beta) type I receptor/ALK-5 and Smad proteins mediate epithelial to mesenchymal transdifferentiation in NMuMG breast epithelial cells. J Cell Sci 1999, 112:4557-4568.
6. Narayan S, Thangasamy T, Balusu R. Transforming growth factor -beta receptor signaling in cancer. Front Biosci 2005, 10:1135-1145. 10.2741/1606, 15769612.
7. Inman GJ, Nicolas FJ, Hill CS. Nucleocytoplasmic shuttling of Smads 2, 3, and 4 permits sensing of TGF-beta receptor activity. Mol Cell 2002, 10:283-294. 10.1016/S1097-2765(02)00585-3, 12191474.
8. Massague J, Gomis RR. The logic of TGFbeta signaling. FEBS Lett 2006, 580:2811-2820. 10.1016/j.febslet.2006.04.033, 16678165.
9. Bharathy S, Xie W, Yingling JM, Reiss M. Cancer-associated transforming growth factor beta type II receptor gene mutant causes activation of bone morphogenic protein-Smads and invasive phenotype. Cancer Res 2008, 68:1656-1666. 10.1158/0008-5472.CAN-07-5089, 2667898, 18339844.
10. Liu IM, Schilling SH, Knouse KA, Choy L, Derynck R, Wang XF. TGFbeta-stimulated Smad1/5 phosphorylation requires the ALK5 L45 loop and mediates the pro-migratory TGFbeta switch. EMBO J 2009, 28:88-98. 10.1038/emboj.2008.266, 2634733, 19096363.
11. Daly AC, Randall RA, Hill CS. Transforming growth factor beta-induced Smad1/5 phosphorylation in epithelial cells is mediated by novel receptor complexes and is essential for anchorage-independent growth. Mol Cell Biol 2008, 28:6889-6902. 10.1128/MCB.01192-08, 2573298, 18794361.
12. Nikolic-Vukosavljevic D, Todorovic-Rakovic N, Demajo M, Ivanovic V, Neskovic B, Markicevic M, Neskovic-Konstantinovic Z. Plasma TGF-beta1-related survival of postmenopausal metastatic breast cancer patients. Clin Exp Metastasis 2004, 21:581-585. 10.1007/s10585-004-4978-1, 15787095.
13. Ivanovic V, Demajo M, Krtolica K, Krajnovic M, Konstantinovic M, Baltic V, Prtenjak G, Stojiljkovic B, Breberina M, Neskovic-Konstantinovic Z, et al. Elevated plasma TGF-beta1 levels correlate with decreased survival of metastatic breast cancer patients. Clin Chim Acta 2006, 371:191-193. 10.1016/j.cca.2006.02.027, 16650397.
14. Grau AM, Wen W, Ramroopsingh DS, Gao YT, Zi J, Cai Q, Shu XO, Zheng W. Circulating transforming growth factor-beta-1 and breast cancer prognosis: results from the Shanghai Breast Cancer Study. Breast Cancer Res Treat 2007,
15. O'Brien PJ, Ramanathan R, Yingling JM, Baselga J, Rothenberg ML, Carducci M, Daly T, Adcock D, Lahn M. Analysis and variability of TGFbeta measurements in cancer patients with skeletal metastases. Biologics 2008, 2:563-569. 2721365, 19707386.
16. Dalal BI, Keown PA, Greenberg AH. Immunocytochemical localization of secreted transforming growth factor-beta 1 to the advancing edges of primary tumors and to lymph node metastases of human mammary carcinoma. Am J Pathol 1993, 143:381-389. 1887030, 8393616.
17. MacCallum J, Bartlett JM, Thompson AM, Keen JC, Dixon JM, Miller WR. Expression of transforming growth factor beta mRNA isoforms in human breast cancer [see comments]. Br J Cancer 1994, 69:1006-1009. 1969445, 8198961.
18. McCune BK, Mullin BR, Flanders KC, Jaffurs WJ, Mullen LT, Sporn MB. Localization of transforming growth factor-beta isotypes in lesions of the human breast [see comments]. Hum Pathol 1992, 23:13-20. 10.1016/0046-8177(92)90004-M, 1544664.
19. Walker RA, Dearing SJ. Transforming growth factor beta 1 in ductal carcinoma in situ and invasive carcinomas of the breast. Eur J Cancer 1992, 28:641-644. 10.1016/S0959-8049(05)80116-9, 1317202.
20. Gorsch SM, Memoli VA, Stukel TA, Gold LI, Arrick BA. Immunohistochemical staining for transforming growth factor beta 1 associates with disease progression in human breast cancer. Cancer Res 1992, 52:6949-6952.
21. Tan AR, Alexe G, Reiss M. Transforming growth factor-beta signaling: emerging stem cell target in metastatic breast cancer?. Breast Cancer Res Treat 2009, 115:453-495. 10.1007/s10549-008-0184-1, 2693232, 18841463.
22. McEarchern JA, Kobie JJ, Mack V, Wu RS, Meade-Tollin L, Arteaga CL, Dumont N, Besselsen D, Seftor E, Hendrix MJ, et al. Invasion and metastasis of a mammary tumor involves TGF-beta signaling. Int J Cancer 2001, 91:76-82. 10.1002/1097-0215(20010101)91:1<76::AID-IJC1012>3.0.CO;2-8, 11149423.
23. Yin JJ, Selander K, Chirgwin JM, Dallas M, Grubbs BG, Wieser R, Massague J, Mundy GR, Guise TA. TGF-beta signaling blockade inhibits PTHrP secretion by breast cancer cells and bone metastases development. J Clin Invest 1999, 103:197-206. 10.1172/JCI3523, 407876, 9916131.
24. Tang B, Vu M, Booker T, Santner SJ, Miller FR, Anver MR, Wakefield LM. TGF-{beta} switches from tumor suppressor to prometastatic factor in a model of breast cancer progression. J Clin Invest 2003, 112:1116-1124. 198530, 14523048.
25. Kang Y, He W, Tulley S, Gupta GP, Serganova I, Chen CR, Manova-Todorova K, Blasberg R, Gerald WL, Massague J. Breast cancer bone metastasis mediated by the Smad tumor suppressor pathway. Proc Natl Acad Sci USA 2005, 102:13909-13914. 10.1073/pnas.0506517102, 1236573, 16172383.
26. Deckers M, van Dinther M, Buijs J, Que I, Lowik C, Pluijm G, ten Dijke P. The tumor suppressor Smad4 is required for transforming growth factor beta-induced epithelial to mesenchymal transition and bone metastasis of breast cancer cells. Cancer Res 2006, 66:2202-2209. 10.1158/0008-5472.CAN-05-3560, 16489022.
27. Korpal M, Yan J, Lu X, Xu S, Lerit DA, Kang Y. Imaging transforming growth factor-beta signaling dynamics and therapeutic response in breast cancer bone metastasis. Nat Med 2009, 15:960-966. 10.1038/nm.1943, 19597504.
28. Kakonen SM, Selander KS, Chirgwin JM, Yin JJ, Burns S, Rankin WA, Grubbs BG, Dallas M, Cui Y, Guise TA. Transforming growth factor-beta stimulates parathyroid hormone-related protein and osteolytic metastases via Smad and mitogen-activated protein kinase signaling pathways. J Biol Chem 2002, 277:24571-24578. 10.1074/jbc.M202561200, 11964407.
29. Tian F, DaCosta Byfield S, Parks WT, Yoo S, Felici A, Tang B, Piek E, Wakefield LM, Roberts AB. Reduction in Smad2/3 signaling enhances tumorigenesis but suppresses metastasis of breast cancer cell lines. Cancer Res 2003, 63:8284-8292.
30. Reiss M. Transforming Growth Factor-β in metastasis: In vitro and in vivo mechanisms. Transforming Growth Factor-beta in Cancer Therapy 2008, II:609-634. Totowa, NY: The Humana Press, Inc, Jakowlew SB.
31. Dumont N, Arteaga CL. Targeting the TGF beta signaling network in human neoplasia. Cancer Cell 2003, 3:531-536. 10.1016/S1535-6108(03)00135-1, 12842082.
32. Saunier EF, Akhurst RJ. TGF beta inhibition for cancer therapy. Curr Cancer Drug Targets 2006, 6:565-578. 10.2174/156800906778742460, 17100564.
33. Yingling JM, Blanchard KL, Sawyer JS. Development of TGF-beta signalling inhibitors for cancer therapy. Nat Rev Drug Discov 2004, 3:1011-1022. 10.1038/nrd1580, 15573100.
34. Russo LM, Brown D, Lin HY. The soluble transforming growth factor-beta receptor: advantages and applications. Int J Biochem Cell Biol 2009, 41:472-476. 10.1016/j.biocel.2008.01.026, 18339576.
35. Dasch JR, Pace DR, Waegell W, Inenaga D, Ellingsworth L. Monoclonal antibodies recognizing transforming growth factor-beta. Bioactivity neutralization and transforming growth factor beta 2 affinity purification. J Immunol 1989, 142:1536-1541.
36. Singh J, Chuaqui CE, Boriack-Sjodin PA, Lee WC, Pontz T, Corbley MJ, Cheung HK, Arduini RM, Mead JN, Newman MN, et al. Successful shape-based virtual screening: the discovery of a potent inhibitor of the type I TGFbeta receptor kinase (TbetaRI). Bioorg Med Chem Lett 2003, 13:4355-4359. 10.1016/j.bmcl.2003.09.028, 14643325.
37. DaCosta Byfield S, Major C, Laping NJ, Roberts AB. SB-505124 Is a Selective Inhibitor of Transforming Growth Factor-{beta} Type I Receptors ALK4, ALK5, and ALK7. Mol Pharmacol 2004, 65:744-752. 10.1124/mol.65.3.744, 14978253.
38. Hjelmeland MD, Hjelmeland AB, Sathornsumetee S, Reese ED, Herbstreith MH, Laping NJ, Friedman HS, Bigner DD, Wang XF, Rich JN. SB-431542, a small molecule transforming growth factor-beta-receptor antagonist, inhibits human glioma cell line proliferation and motility. Mol Cancer Ther 2004, 3:737-745.
39. Ge R, Rajeev V, Subramanian G, Reiss KA, Liu D, Higgins L, Joly A, Dugar S, Chakravarty J, Henson M, et al. Selective inhibitors of type I receptor kinase block cellular transforming growth factor-beta signaling. Biochem Pharmacol 2004, 68:41-50. 10.1016/j.bcp.2004.03.011, 15183116.
40. Li HY, McMillen WT, Heap CR, McCann DJ, Yan L, Campbell RM, Mundla SR, King CH, Dierks EA, Anderson BD, et al. Optimization of a dihydropyrrolopyrazole series of transforming growth factor-beta type I receptor kinase domain inhibitors: discovery of an orally bioavailable transforming growth factor-beta receptor type I inhibitor as antitumor agent. J Med Chem 2008, 51:2302-2306. 10.1021/jm701199p, 18314943.
41. Kareddula A, Zachariah E, Notterman D, Reiss M. Transforming Growth Factor-β Signaling Strength Determines Target Gene Expression Profile in Human Keratinocytes. J Epithel Biol Pharmacol 2008, 1:40-94.
42. Kang Y, Siegel PM, Shu W, Drobnjak M, Kakonen SM, Cordon-Cardo C, Guise TA, Massague J. A multigenic program mediating breast cancer metastasis to bone. Cancer Cell 2003, 3:537-549. 10.1016/S1535-6108(03)00132-6, 12842083.
43. Minn AJ, Gupta GP, Siegel PM, Bos PD, Shu W, Giri DD, Viale A, Olshen AB, Gerald WL, Massague J. Genes that mediate breast cancer metastasis to lung. Nature 2005, 436:518-524. 10.1038/nature03799, 1283098, 16049480.
44. Kang Y. Breast cancer bone metastasis: molecular basis of tissue tropism. J Musculoskelet Neuronal Interact 2004, 4:379-380.
45. Kang Y, Chen CR, Massague J. A self-enabling TGFbeta response coupled to stress signaling: Smad engages stress response factor ATF3 for Id1 repression in epithelial cells. Mol Cell 2003, 11:915-926. 10.1016/S1097-2765(03)00109-6, 12718878.
46. Kenny P, Lee G, Myers C, Neve R, Semeiks J, Spellman P, Lorenz K, Lee E, Barcellos-Hoff M, Petersen O, et al. The morphologies of breast cancer cell lines in three-dimensional assays correlate with their profiles of gene expression. Molecular Oncology 2007, 1:84-96. 10.1016/j.molonc.2007.02.004, 2391005, 18516279.
47. Muraoka RS, Dumont N, Ritter CA, Dugger TC, Brantley DM, Chen J, Easterly E, Roebuck LR, Ryan S, Gotwals PJ, et al. Blockade of TGF-beta inhibits mammary tumor cell viability, migration, and metastases. J Clin Invest 2002, 109:1551-1559. 151012, 12070302.
48. Ge R, Rajeev V, Ray P, Lattime E, Rittling S, Medicherla S, Protter A, Murphy A, Chakravarty J, Dugar S, et al. Inhibition of growth and metastasis of mouse mammary carcinoma by selective inhibitor of transforming growth factor-beta type I receptor kinase in vivo. Clin Cancer Res 2006, 12:4315-4330. 10.1158/1078-0432.CCR-06-0162, 16857807.
49. Arteaga CL, Hurd SD, Winnier AR, Johnson MD, Fendly BM, Forbes JT. Anti-transforming growth factor (TGF)-beta antibodies inhibit breast cancer cell tumorigenicity and increase mouse spleen natural killer cell activity. Implications for a possible role of tumor cell/host TGF-beta interactions in human breast cancer progression. J Clin Invest 1993, 92:2569-2576. 10.1172/JCI116871, 288452, 7504687.
50. Ehata S, Hanyu A, Fujime M, Katsuno Y, Fukunaga E, Goto K, Ishikawa Y, Nomura K, Yokoo H, Shimizu T, et al. Ki26894, a novel transforming growth factor beta type I receptor kinase inhibitor, inhibits in vitro invasion and in vivo bone metastasis of a human breast cancer cell line. Cancer Sci 2007, 98:127-133. 10.1111/j.1349-7006.2006.00357.x, 17129361.
51. Pinkas J, Teicher BA. TGF-beta in cancer and as a therapeutic target. Biochem Pharmacol 2006, 72:523-529. 10.1016/j.bcp.2006.03.004, 16620790.
52. Nam JS, Suchar AM, Kang MJ, Stuelten CH, Tang B, Michalowska AM, Fisher LW, Fedarko NS, Jain A, Pinkas J, et al. Bone sialoprotein mediates the tumor cell-targeted prometastatic activity of transforming growth factor beta in a mouse model of breast cancer. Cancer Res 2006, 66:6327-6335. 10.1158/0008-5472.CAN-06-0068, 1528715, 16778210.
53. Nam JS, Terabe M, Kang MJ, Chae H, Voong N, Yang YA, Laurence A, Michalowska A, Mamura M, Lonning S, et al. Transforming growth factor beta subverts the immune system into directly promoting tumor growth through interleukin-17. Cancer Res 2008, 68:3915-3923. 10.1158/0008-5472.CAN-08-0206, 2586596, 18483277.
54. Nam JS, Terabe M, Mamura M, Kang MJ, Chae H, Stuelten C, Kohn E, Tang B, Sabzevari H, Anver MR, et al. An anti-transforming growth factor beta antibody suppresses metastasis via cooperative effects on multiple cell compartments. Cancer Res 2008, 68:3835-3843. 10.1158/0008-5472.CAN-08-0215, 2587151, 18483268.
55. Miettinen PJ, Ebner R, Lopez AR, Derynck R. TGF-beta induced transdifferentiation of mammary epithelial cells to mesenchymal cells: involvement of type I receptors. Journal of Cell Biology 1994, 127:2021-2036. 10.1083/jcb.127.6.2021, 2120317, 7806579.
56. Wrighton KH, Lin X, Yu PB, Feng XH. Transforming Growth Factor {beta} Can Stimulate Smad1 Phosphorylation Independently of Bone Morphogenic Protein Receptors. J Biol Chem 2009, 284:9755-9763. 10.1074/jbc.M809223200, 2665096, 19224917.
57. Futakuchi M, Nannuru KC, Varney ML, Sadanandam A, Nakao K, Asai K, Shirai T, Sato SY, Singh RK. Transforming growth factor-beta signaling at the tumor-bone interface promotes mammary tumor growth and osteoclast activation. Cancer Sci 2009, 100:71-81. 10.1111/j.1349-7006.2008.01012.x, 19038005.
58. Mohammad KS, Chen CG, Balooch G, Stebbins E, McKenna CR, Davis H, Niewolna M, Peng XH, Nguyen DH, Ionova-Martin SS, et al. Pharmacologic inhibition of the tgf-Beta type I receptor kinase has anabolic and anti-catabolic effects on bone. PLoS ONE 2009, 4:e5275. 10.1371/journal.pone.0005275, 2666804, 19357790.
59. Carano R, Li Y, Bao M, Li J, Berry L, Ross J, Kowalski J, French D, Dugger D, Schwall R, et al. Effect of anti-TGF-beta antibodies in syngeneic mouse models of metastasis. J Musculoskelet Neuronal Interact 2004, 4:377-378.
60. Debnath J, Muthuswamy SK, Brugge JS. Morphogenesis and oncogenesis of MCF-10A mammary epithelial acini grown in three-dimensional basement membrane cultures. Methods 2003, 30:256-268. 10.1016/S1046-2023(03)00032-X, 12798140.
61. Yu L, Border WA, Anderson I, McCourt M, Huang Y, Noble NA. Combining TGF-beta inhibition and angiotensin II blockade results in enhanced antifibrotic effect. Kidney Int 2004, 66:1774-1784. 10.1111/j.1523-1755.2004.00901.x, 15496148.
62. Li HY, Wang Y, Heap CR, King CH, Mundla SR, Voss M, Clawson DK, Yan L, Campbell RM, Anderson BD, et al. Dihydropyrrolopyrazole transforming growth factor-beta type I receptor kinase domain inhibitors: a novel benzimidazole series with selectivity versus transforming growth factor-beta type II receptor kinase and mixed lineage kinase-7. J Med Chem 2006, 49:2138-2142. 10.1021/jm058209g, 16539403.